Arg-Gly-Asp-Ser

Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.

Product Specifications

CAS Number

[91037-65-9]

Product Name Alternative

RGDS peptide; Fibronectin tetrapeptide

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

Integrin

Type

Peptides

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Arg-Gly-Asp-Ser.html

Purity

99.09

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 25 mg/mL

Smiles

O=C(N[C@@H](CO)C(O)=O)[C@H](CC(O)=O)NC(CNC([C@@H](N)CCCNC(N)=N)=O)=O

Molecular Formula

C15H27N7O8

Molecular Weight

433.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Grigoriou V, et al. Apoptosis and survival of osteoblast-like cells are regulated by surface attachment. J Biol Chem. 2005 Jan 21;280 (3) :1733-9.|[2]Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.|[3]Yin X, et al. Synthetic RGDS peptide attenuated lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. J Gastroenterol Hepatol. 2014 Jun;29 (6) :1308-15.|[4]Aguzzi MS, et al. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer. 2010 Apr 22;9:84.